{"filings":[{"id":68881,"accession_number":"0001753926-26-000854","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2026-05-13T20:25:45+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical reports Q1 2026 net loss of $6.8M; SLIM-1 trial on track for mid-2026","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.8M in Q1 2026, up from $6.3M in Q1 2025; R&D expense $4.4M (+4% YoY).","Cash, equivalents and capital commitments of $28M expected to fund operations through first half of 2027.","Raised $9.7M in financing in Q1 2026, including $2.2M from a registered direct offering.","SLIM-1 Phase 1 trial of NPM-139 semaglutide implant to start mid-2026; top-line results by end of 2026.","Cortigent spin-off or IPO under consideration; S-1 amendment filed May 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102187,"accession_number":"0001753926-26-000550","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivani Medical reports FY2025 net loss $26.6M; advances semaglutide implant NPM-139 towards Phase 1","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss $26.6M vs $23.5M in FY2024; R&D expenses $18.1M up 15% YoY.","Cash $16.2M as of Dec 31, 2025; raised $41.5M gross from financings; funds ops into mid-2027.","Successful LIBERATE-1 first-in-human study; preclinical data shows >20% sham-adjusted weight loss for full year with single semaglutide implant.","Phase 1 study of NPM-139 (semaglutide implant) for chronic weight management expected mid-2026 with results by end of 2026.","Exploring spin-off or IPO of subsidiary Cortigent (neuromodulation assets)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102186,"accession_number":"0001753926-26-000194","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical prices $4.5M common stock offering; Chairman participates in private placement","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.5M from registered direct offering (1.69M shares) and private placement (1.35M shares) at $1.48/share.","Chairman Gregg Williams purchased 1,351,351 shares in private placement at same price.","Net proceeds to fund clinical development and working capital; offering expected to close Jan. 27, 2026.","ThinkEquity acted as sole placement agent for the registered direct offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118507,"accession_number":"0001753926-25-001768","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical Q3 net loss $6.5M; plans Phase 1 semaglutide implant study in H1 2026","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.5M in Q3 2025 vs $6.0M in Q3 2024; cash down to $4.0M from $19.7M at year-end 2024.","Closed ~$15.7M in October equity financings and $10M August private placement, total $25.7M cash and commitments.","Plans to initiate Phase 1 clinical study of NPM-139 semaglutide implant for chronic weight management in first half 2026.","Spin-off of Cortigent temporarily withdrawn due to U.S. government shutdown; new record date expected after SEC resumes.","R&D expense $4.5M ($4.2M in Q3 2024); G&A $2.2M ($2.1M in Q3 2024); operating expenses increased $0.4M."],"consensus_eps_estimate":-0.1122,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118506,"accession_number":"0001753926-25-001655","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical prices $15.7M equity offering; Chairman participates in $6.0M private placement","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 6M shares and private placement of 3.7M shares priced at $1.62/share for total gross proceeds of ~$15.7M.","Private placement purchased by Board Chairman Gregg Williams, generating ~$6.0M; no warrants or fees incurred.","ThinkEquity acts as sole placement agent; Company to pay 7% fee plus up to $125k reimbursable expenses.","Closing expected October 28, 2025; proceeds to fund clinical development and working capital; officers subject to 60-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118505,"accession_number":"0001753926-25-001582","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vivani Medical withdraws Cortigent spin-off record date due to US government shutdown","event_type":"other_material","confidence":"high","bullets":["Withdrew record date of October 8, 2025 for proposed spin-off of Cortigent subsidiary.","Delay caused by current shutdown of the U.S. federal government.","Company expects to reestablish and announce a new record date as soon as possible.","ThinkEquity is exclusive financial advisor to Cortigent for the spin-off transaction.","Cortigent develops brain implant devices with neuromodulation technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134962,"accession_number":"0001753926-25-001510","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani sets Oct 8 record date for Cortigent spin-off; Cortigent to trade as CRGT","event_type":"other_material","confidence":"high","bullets":["Record date for Cortigent spin-off is October 8, 2025; distribution date and ratio to be announced later.","Spin-off expected to complete by late-2025; Cortigent will trade on Nasdaq under ticker CRGT.","Cortigent develops brain implants (Orion vision system, stroke recovery device); has completed 6-year feasibility study.","Post spin-off, Vivani focuses on ultra long-acting GLP-1 implants for weight loss and type 2 diabetes.","Management teams will each focus on their respective strategies; Cortigent CEO Jonathan Adams to stay on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134961,"accession_number":"0001753926-25-001443","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vivani Medical files corporate slides; no specific material changes apparent from filing text","event_type":"other_material","confidence":"low","bullets":["Corporate slide presentation filed as Exhibit 99.1, date-stamped September 9, 2025.","Presentation posted on company website under 'Investors' section.","No financial results, product updates, or milestones cited in the 8-K text.","Slides speak as of filing date; company disclaims update obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134960,"accession_number":"0001753926-25-001431","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical plans Phase 1/2 trials for NPM-139 semaglutide implant; H1 2026 start","event_type":"other_material","confidence":"high","bullets":["NPM-139 is a semaglutide implant for chronic weight management in obese/overweight patients.","Phase 1 study expected to start H1 2026 pending regulatory clearance; designed for safety, tolerability, PK.","Phase 2 dose-ranging study planned to follow Phase 1, pending enabling results and regulatory feedback.","NPM-139 aims to deliver Wegovy-level efficacy with once or twice-yearly administration.","Positive preclinical data and promising LIBERATE-1 results for NPM-115 (exenatide) support program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134959,"accession_number":"0001753926-25-001328","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Vivani Medical raises $10M, reports Q2 loss of $7.1M, advances semaglutide implant NPM-139","event_type":"earnings","confidence":"high","bullets":["Raised $10M via private placement of 7.94M shares at $1.26/share with director-affiliated entity.","Q2 2025 net loss $7.1M vs $5.3M in Q2 2024; cash $8.1M as of June 30, 2025.","Positive preclinical data for NPM-139: ~20% weight loss maintained >6 months with single implant.","Plans to initiate NPM-139 clinical program in 2026; spin off Cortigent division in H2 2025.","Appointed Anthony Baldor as CFO; additional $21.25M committed capital through July 2026."],"consensus_eps_estimate":-0.102,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134958,"accession_number":"0001753926-25-001228","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Vivani Medical reports positive Phase 1 data for NPM-115 implant and prioritizes semaglutide implant NPM-139","event_type":"other_material","confidence":"high","bullets":["Preliminary Q2 2025 cash and cash equivalents $6.8M, plus $11.25M committed capital through March 2026.","LIBERATE-1 Phase 1 study of NPM-115 (exenatide implant) met primary safety and PK objectives; no serious adverse events.","Preclinical data for NPM-139 (semaglutide implant) showed ~20% weight loss maintained over 231 days from a single implant.","Vivani prioritizes NPM-139 for clinical development, with IND submission planned and clinical start expected in 2026.","Semaglutide products (Ozempic, Wegovy, Rybelsus) generated over $29B in 2024 sales, supporting prioritization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151906,"accession_number":"0001753926-25-001005","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vivani Medical stockholders elect board, ratify auditor, approve say-on-pay at annual meeting","event_type":"other","confidence":"high","bullets":["Elected all six director nominees: Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Popoff, Adam Mendelsohn, Daniel Bradbury.","Ratified BPM LLP as independent auditor for FY 2025, with 36.5M votes for, 98K against.","Advisory vote approved named executive officer compensation, with 23.1M for, 594K against, and 1.7M abstentions.","A quorum of 37.1M shares out of 59.2M outstanding was represented at the June 24, 2025 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151905,"accession_number":"0001753926-25-000966","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vivani Medical reports exenatide implant cuts liver fat 82% in obese mice","event_type":"other_material","confidence":"high","bullets":["Exenatide implant reduced liver fat by 82% vs sham in high-fat diet obese mice after 12 weeks (Oil Red O staining).","Exenatide delivered via NanoPortal technology showed durable body weight reduction in rats over 105-140 days.","Findings from corporate slide presentation furnished as Exhibit 99.1; no material financial updates.","Vivani is developing NPM-119 (exenatide implant) for metabolic indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151904,"accession_number":"0001753926-25-000956","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical appoints Anthony Baldor as CFO, Brigid Makes resigns","event_type":"leadership","confidence":"high","bullets":["CFO Brigid Makes resigns effective June 15, 2025; no disagreement with company.","Anthony Baldor appointed CFO, Principal Financial Officer and Principal Accounting Officer effective June 15, 2025.","Baldor previously CFO at Diakonos Oncology and VP at 4D Molecular Therapeutics.","Baldor receives $450,000 base salary, performance bonus, and option for 600,000 shares vesting over 4 years.","Makes will serve in advisory capacity during transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151903,"accession_number":"0001753926-25-000898","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical files Form 10 for spin-off of Cortigent; expects Nasdaq listing in Q3 2025","event_type":"m_and_a","confidence":"high","bullets":["Cortigent files Form 10 to spin off from Vivani as independent Nasdaq company; completion expected Q3 2025.","Orion Visual Cortical Prosthesis completed Early Feasibility Study in March 2025; has FDA Breakthrough Device designation.","Cortigent advancing Stroke Recovery System to improve arm/hand movement recovery after stroke paralysis.","Vivani will focus solely on NanoPortal GLP-1 implants for chronic weight management and type 2 diabetes.","Spin-off requires final board approval, tax opinion, and SEC/Nasdaq clearance; shares distributed to Vivani stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}